-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-6301 in Chordoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GI-6301 in Chordoma Drug Details: GI-6301 is under development for the treatment of chordoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Food Allergy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GI-301 in Food Allergy Drug Details:GI-301 is under development for chronic idiopathic urticarial (CIU), atopic dermatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Allergic Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GI-301 in Allergic Asthma Drug Details:GI-301 is under development for chronic idiopathic urticarial (CIU), atopic dermatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-301 in Chronic Urticaria Or Hives
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GI-301 in Chronic Urticaria Or Hives Drug Details:GI-301 is under development for chronic idiopathic urticarial (CIU),...
-
Product Insights
New![]()
Net Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GI-XBI-302 in Graft Versus Host Disease (GVHD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-XBI-302 in Graft Versus Host Disease (GVHD) Drug Details: GI-XBI-302 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus InfectionsDrug Details:The vaccine candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Gi.1 + Gii.4] (Bivalent, Virus-Like Particle) Vaccine in Norovirus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Gi.1 + Gii.4] (Bivalent, Virus-Like Particle) Vaccine in Norovirus InfectionsDrug Details:Vaccine candidate is under...
-
Company Profile
![]()
Motus GI Holdings Inc – Company Profile
Motus GI Holdings Inc (Motus GI) is a developer of medical technologies. The company carries out developing a single-use medical device system Pure-Vu system which consists of two sub-products such as disposable single-use sleeve and a workstation controller. Its product is mainly used for early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company operates through various geographical regions including the US and Israel. Motus GI is headquartered in Fort Lauderdale, Florida, the...
Add to Basket -
Product Insights
Delhi Trans – Gopalpur GIS Substation – NCT
Equip yourself with the essential tools needed to make informed and profitable decisions with our Delhi Trans - Gopalpur GIS Substation - NCT report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Gies Clg – South Campus Center for Interdisciplinary Learning Building – Illinois
Equip yourself with the essential tools needed to make informed and profitable decisions with our Gies Clg - South Campus Center for Interdisciplinary Learning Building - Illinois report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
WGH Herrenhausen – Burg GI-Carree Residential Complex – Lower Saxony
Equip yourself with the essential tools needed to make informed and profitable decisions with our WGH Herrenhausen - Burg GI-Carree Residential Complex - Lower Saxony report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
DMG Cap/ GIS Int – 415 E. 25th St Tacoma Trax Mixed Use Development – Washington
Equip yourself with the essential tools needed to make informed and profitable decisions with our DMG Cap/ GIS Int - 415 E. 25th St Tacoma Trax Mixed Use Development - Washington report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report?...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GLM1RA in Gastric Ulcers
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GLM1RA in Gastric Ulcers Drug Details: GLM1RA is under development for the treatment of gastrointestinal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HIL-214 in Gastroenteritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HIL-214 in GastroenteritisDrug Details:HIL-214 was under development for the prevention of acute gastroenteritis caused by norovirus....
-
Product Insights
New![]()
Net Present Value Model: GSK plc’s GSK-3036656
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-207 in Anal Fistula
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AB-207 in Anal FistulaDrug Details:E-CEL UVEC is under development for the treatment of anal fistula, 2nd GI...
-
Sector Analysis
NewOman Insurance Industry – Key Trends and Opportunities to 2027
Oman Insurance Industry Report Overview The total gross written premiums (GWP) in the Oman insurance industry were OMR549.8 million in 2022 and is expected to record a CAGR of more than 6% during 2023-2027. The Oman insurance industry report provides in-depth market analysis, information, and insights into the Oman insurance industry. The report has a comprehensive overview of the Oman economy, government initiatives, and investment opportunities. Oman Insurance Industry Outlook 2022-2027 (OMR million) Buy the Full Report or Download a...
-
Product Insights
Saudi Electricity – Reactors at MKH, JNE, RBG-2 & GIS at MHLW – Makkah
Equip yourself with the essential tools needed to make informed and profitable decisions with our Saudi Electricity - Reactors at MKH, JNE, RBG-2 & GIS at MHLW - Makkah report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Thematic Analysis
New![]()
Construction Industry Mergers and Acquisitions Deals by Top Themes in Q2 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q2 2023 in the Construction Sector
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.